Biotech Optimism at Festival of Biologics: Precision Therapies and the Future of Cell Therapies

This title was summarized by AI from the post below.
View profile for Chase Blakeley
Chase Blakeley

I spent the first week of March in San Diego at the Festival of Biologics. The energy at the conference was a reminder that while the biotech market has been difficult, the optimism for new modalities is very much alive. The consensus among the teams I spoke with is that we are reaching a ceiling with current cell therapies. We have proven we can kill cancer cells, but we are still struggling to do it without damaging healthy tissue. Most of the technical conversations kept returning to the same problem: precision. At GoCART, our approach is to move beyond simple binding and toward actual biological logic. Our platform uses a physical AND-gate to ensure therapy only activates when two specific markers are present on a tumor. This spatial coincidence sensing is what allows us to target indications like Multiple Myeloma and AML that were previously considered too risky for this type of treatment. Leaving San Diego, it is clear that the future of this field belongs to those who can solve the toxicity bottleneck. We are focused on building the operating system that makes that precision possible. I am looking forward to the next few months as we move our current validation work toward the clinic.

To view or add a comment, sign in

More Relevant Posts

Chase Blakeley

1,026 followers

View Profile

Explore related topics

Explore content categories